middl
east
respiratori
syndrom
coronaviru
merscov
novel
human
coronaviru
hcov
caus
case
case
cluster
sever
acut
respiratori
syndrom
countri
arabian
peninsula
sinc
least
april
export
infect
report
unit
kingdom
germani
franc
itali
tunisia
total
laboratoryconfirm
case
report
date
fatal
unknown
whether
viru
enter
human
popul
zoonot
sourc
ensu
local
transmiss
chain
altern
whether
circul
continu
human
recent
analys
base
molecular
clock
assumpt
phylogeni
estim
recent
common
ancestor
present
known
virus
exist
remain
unknown
whether
ancestor
continu
exist
anim
andor
human
whether
merscov
respons
case
identifi
thu
far
spread
among
human
recent
studi
provid
evid
virusneutr
antibodi
dromedari
camel
howev
studi
distribut
viru
either
human
anim
perform
date
view
uncertain
epidemiolog
crosssect
investig
exist
antibodi
human
popul
interest
detect
antibodi
larg
part
popul
would
suggest
widespread
longstand
circul
merscov
contrast
absenc
antibodi
would
suggest
larg
portion
popul
suscept
infect
increas
risk
epidem
final
comparison
antibodi
preval
among
human
expos
versu
expos
livestock
could
provid
clue
potenti
sourc
zoonot
infect
test
human
popul
hcov
antibodi
highli
demand
technic
perspect
titer
gener
low
crossreact
hcov
within
beyond
viral
genera
particular
limit
inform
crossreact
antibodi
known
hcov
hcov
antibodi
merscov
uncertainti
recent
propos
stage
approach
merscov
serolog
consist
firstlin
screen
immunofluoresc
assay
ifa
evalu
discrimin
recombin
ifa
use
recombin
spike
protein
establish
hcov
plaquereduct
neutral
test
confirm
specif
reactiv
merscov
use
method
investig
human
serum
specimen
includ
slaughterhous
employe
jeddah
makkah
saudi
arabia
one
first
human
case
merscov
infect
diagnos
ifa
use
full
merscov
perform
commerci
avail
test
kit
antimerscov
iift
euroimmun
ag
germani
exactli
describ
elsewher
discriminatori
recombin
ifa
follow
describ
protocol
extend
purpos
studi
includ
full
spike
protein
complet
open
read
frame
hcov
merscov
express
eukaryot
express
vector
serum
neutral
test
vero
cell
grown
subconflu
plate
preincub
reaction
contain
plaqueform
unit
merscov
emc
strain
medium
mix
patient
serum
specimen
predilut
medium
start
dilut
hour
incub
well
infect
hour
use
total
preincub
reaction
supernat
remov
overlaid
avicel
resin
exactli
describ
herzog
et
al
assay
termin
stain
immers
formaldehydecryst
violet
solut
day
therebi
inactiv
test
viru
neutral
titer
defin
serum
dilut
reduc
number
plaqu
parallel
well
summari
enrol
slaughterhous
worker
gave
blood
voluntarili
provid
written
inform
consent
blood
sampl
test
merscov
antibodi
first
orient
assess
antibodi
local
popul
anonym
panel
serum
specimen
healthi
blood
donor
assembl
individu
submit
blood
donor
elig
screen
king
abdulaziz
univers
hospit
jeddah
januari
decemb
sampl
test
predilut
ifa
describ
elsewher
yield
specif
fluoresc
signal
case
note
previou
studi
ifa
serum
specimen
blood
donor
crossreact
dilut
report
potenti
exposur
livestock
anim
mer
case
worker
slaughterhous
jeddah
slaughterhous
makkah
investig
octob
slaughter
anim
includ
cattl
camel
sheep
worker
age
year
work
slaughterhous
interv
rang
month
year
variou
countri
includ
bangladesh
n
burkina
faso
n
egypt
n
india
n
mali
n
niger
n
pakistan
n
saudi
arabia
n
sudan
n
yemen
n
worker
live
saudi
arabia
durat
rang
month
year
upon
initi
screen
use
ifa
slide
contain
cell
infect
full
merscov
serum
specimen
yield
specif
ifa
pattern
appar
differ
detect
rate
individu
studi
site
tabl
sampl
investig
use
discrimin
recombin
ifa
summar
tabl
specimen
show
domin
titer
recombin
spike
protein
hcov
merscov
specimen
react
merscov
contrast
specimen
subject
laboratoryconfirm
mer
show
clear
reactiv
recombin
merscov
spike
protein
patient
specimen
concomit
reactiv
spike
protein
hcov
well
expect
recenc
merscov
infect
patient
involv
lowavid
antibodi
patient
antimerscov
immunoglobulin
posit
sampl
addit
test
presenc
neutral
antibodi
detect
serum
neutral
serum
specimen
incub
plaqueform
unit
merscov
strain
hour
adsorb
onto
vero
cell
anoth
hour
cell
overlaid
avicel
resin
incub
day
serum
dilut
affect
reduct
cumul
number
result
plaqu
replic
assay
record
serum
neutral
titer
nt
serum
dilut
appear
nt
small
fraction
blood
sampl
healthi
german
adult
antimerscov
antibodi
dilut
chosen
titrat
limit
ie
start
dilut
neutral
assay
summar
tabl
none
specimen
serum
neutral
titer
titrat
limit
wherea
serum
specimen
patient
laboratoryconfirm
merscov
infect
clear
neutral
titer
investig
yield
major
conclus
first
demonstr
immunofluoresc
analysi
use
virusinfect
merscovinfect
cell
use
viral
antigen
abbrevi
sh
slaughterhous
cell
perform
alon
rather
part
set
analys
return
falseposit
merscov
antibodi
result
fraction
patient
note
ifa
consid
highli
robust
assay
possibl
inspect
specif
fluoresc
stain
pattern
virusinfect
cell
provid
addit
diagnost
criterion
avail
serolog
format
enzym
immunoassay
eia
propens
falseposit
result
therefor
expect
eia
use
full
viru
test
antigen
futur
studi
take
account
avoid
falseposit
end
point
exact
delin
specif
antigen
epitop
within
merscov
spike
protein
could
use
recombin
antigen
eia
could
use
develop
morereli
protocol
serolog
detect
merscov
second
found
signific
rate
antibodi
merscov
individu
live
jeddah
makkah
region
howev
number
sampl
analyz
preliminari
studi
limit
make
imposs
statist
perspect
exclud
presenc
antibodi
popul
furthermor
although
know
ifa
readili
detect
antibodi
clinic
sever
case
merscov
infect
conceiv
lower
level
antibodi
could
exist
mild
asymptomat
case
nevertheless
believ
data
suggest
longterm
circul
merscov
popul
level
occur
area
target
popul
sampl
popul
therefor
larg
suscept
merscov
infect
note
investig
geograph
area
overlap
destin
hajj
umrah
million
pilgrim
gather
year
respiratori
virus
known
acquir
transmit
high
rate
absenc
antibodi
studi
consist
absenc
report
merscov
infect
pilgrim
return
hajj
abbrevi
ifa
immunofluoresc
assay
merscov
middl
east
respiratori
syndrom
coronaviru
prnt
plaquereduct
neutral
assay
sh
slaughterhous
uae
unit
arab
emir
neg
borderlin
reactiv
weakli
posit
posit
strongli
posit
patient
control
sampl
obtain
describ
elsewher
